Viewing Company Biogen IDEC Inc. | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Biogen IDEC Inc. Stock Symbol: BIIB-Q

Last Price Recorded: $318.4600 on 2017-09-22

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2017-09-14 DON'T BUY Paul Macdonald

It has a large franchise in MS which comprises 75% of their business.  He is seeing potential threat to this franchise from two companies.  Their Alzheimer’ drug comes to trial in 2019 and has high risk.


Price:
$323.660
Subject:
HEALTHCARE
Bias:
SELECTIVE
Owned:
Unknown
2017-06-28 COMMENT Jason Mann

US healthcare for the long-term? As opposed to picking just one stock in a sector, your best bet probably is an ETF. If you are looking for an individual stock, one that he holds is Biogen. It is quite cheap relative to its ability to grow earnings.


Price:
$274.640
Subject:
NORTH AMERICAN
Bias:
UNKNOWN
Owned:
Yes
2017-05-10 COMMENT Paul Macdonald

He doesn’t own this because of their concentration in the MS market. There are 2 other companies in this area with possible better drugs. He feels there are going to be very binary outcomes with no dividends. Prefers something with a little more diversity.


Price:
$257.920
Subject:
HEALTHCARE
Bias:
UNKNOWN
Owned:
No
2017-03-16 TOP PICK Gordon Reid

A bio pharmaceutical. If you look at the traditional Pharma space, the chemical-based companies, the bio-based companies were always out there, coming along, but basically not making a lot of money and were often single drug companies, virtually reinvesting all their cash flow. They have now matured and into much stronger growth companies than the traditional pharmas. They also have lower multiples than they did 5-6 years ago. That makes it quite attractive. (Analysts’ price target is $305.)


Price:
$278.960
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2016-11-22 HOLD David Burrows

(Market Call Minute.) Many people thought the Biotech sector would behave better if Trump got elected. It has had a lift, but it remains to be seen if it can be followed through.


Price:
$318.110
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2016-08-15 BUY John Zechner

(Market Call Minute.) One of the better growth stories in the US biotech side. They have more of a product portfolio and they have cash. Valuation is in line with the market.


Price:
$313.390
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Unknown
2016-06-22 COMMENT Paul Macdonald

Amgen (AMGN-Q), Celgene (CELG-Q) or Biogen (BIIB-Q)? These are 3 great companies. His preference would be Amgen, the leader in the space and the dominant player. This one is a great example of a mega-cap company that has a lot of pent-up interest in one of their phase III’s. Alzheimer’s hasn’t had a great success rate in drug testing, but if it does come positive, you could see some great valuation.


Price:
$234.600
Subject:
HEALTHCARE
Bias:
UNKNOWN
Owned:
No
2016-03-15 PAST TOP PICK David Burrows

(A Top Pick March 10/15. Down 39.56%.) For about 3 years Biotech was one of the leading groups in the market. He stays in positions as long as they work, and runs Stop Losses. In July, biotech as a group rolled over and he got stopped out at about $308-$310.


Price:
$250.330
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
No
2016-02-18 PAST TOP PICK David Burrows

(Top Pick Mar 10/15, Down 36.01%)  He got stopped out last March.  They missed a number.  He is not buying biotech right now.


Price:
$259.050
Subject:
NORTH AMERICAN - LARGE
Bias:
BULL
Owned:
No
2015-07-22 BUY on WEAKNESS Gordon Reid

Has been watching this for a little while. It doesn’t trade at an extreme valuation and they have a nice pipeline. A drug that propelled them recently was their new Alzheimer’s one that is still in testing. A very promising drug. In a short time they are going to come out with the results of a new test on it. He thinks the market will react on this, so he would be hesitant to buy in front of that. If you can buy this in the $350-$375 area, it has a lot of promise.


Price:
$391.740
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
No
2015-04-30 COMMENT Hap (Robert) Sneddon FCSI

This is in the right space to him. It is in a sector that he thinks is going to change humanity in a way the PC changed things in 1982, the way the baby boomers did it coming back from the war, or the 2nd Industrial Revolution. These are large secular pictures that really moved society. They happen in such a way that you actually don’t see the occurrences while you’re in them. If you don’t want to look at this one in particular, you can look at any of the biotech related ETF’s. He doesn’t own any of these, but is waiting with bated breath for an opportunity to do that.


Price:
$373.930
Subject:
TECHNICAL ANALYSIS & MACRO STRATEGY
Bias:
UNKNOWN
Owned:
No
2015-03-10 TOP PICK David Burrows

You have an aging population in the US that is relatively insensitive to price. Last year pharmaceutical prices rose 13%. This company has the dominant market share position in neurological drugs for things such as multiple sclerosis and Alzheimer’s. They have some very important trials in March on Alzheimer’s, which are potentially blockbuster findings. They may either slow down the onset or, more importantly, actually show some reversing. As the Affordable Care act comes in, there are more people that have money to spend on healthcare. In the next couple of years there are lots of additional trials that will come.


Price:
$414.200
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH on US$
Owned:
Yes
2014-04-22 WAIT Jon Vialoux

The period of seasonal strength comes predominately during the summertime, from August through until October. The average gain from July through to October is about 30% on an annual basis. The strongest month is July, so if you can take a position before July, it will give you added value. Currently this is trying to find a bottom. It is bouncing off of oversold levels. Doesn’t expect you would find the bottom at this point. Wait until the summer.


Price:
$306.200
Subject:
SEASONAL & TECHNICAL
Bias:
CAUTIOUS
Owned:
Unknown
2014-01-14 DON'T BUY Brian Acker, CA

(Market Call Minute.) Closed at $283.67 and his model price is $180, a 36% negative. Too expensive here.


Price:
$297.470
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH on US MARKET
Owned:
Unknown
2009-02-19 COMMENT David Burrows Likes Bio Pharma and ethical pharmaceutical companies. Good diversity in their product lines. Good underlying growth.
Price:
$50.760
Subject:
NORTH AMERICAN - LARGE
Bias:
DEFENSIVE
Owned:
Unknown
Showing 1 to 15 of 18 entries
<< < 1 2 > >>

No Comments.


You must be logged in to comment.